Koers Allarity Therapeutics, Inc. Nasdaq Stockholm
Aandelen
ALLR
US0167441049
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | - | Omzet 2025 * | - | Marktkapitalisatie | 442K 4,81 mln. 412K |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -16 mln. -174 mln. -14,92 mln. | Nettowinst (verlies) 2025 * | -28 mln. -305 mln. -26,11 mln. | EV/omzet 2024 * | - |
Nettoliquiditeiten 2024 * | - 0 0 | Nettoliquiditeiten 2025 * | - 0 0 | EV/omzet 2025 * | - |
K/w-verhouding 2024 * |
-0,05
x | K/w-verhouding 2025 * |
-0,05
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 99,98% |
Recentste transcriptie over Allarity Therapeutics, Inc.
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Thomas Jensen
FOU | Founder | 46 | 01-06-20 |
Joan Brown
DFI | Director of Finance/CFO | 71 | 21-09-21 |
Chief Tech/Sci/R&D Officer | 63 | 01-07-21 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Chairman | 56 | 01-10-22 | |
Thomas Jensen
FOU | Founder | 46 | 01-06-20 |
Joseph Vazzano
BRD | Director/Board Member | 40 | 01-08-23 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
-2,26% | 104 mld. | |
+1,41% | 97,42 mld. | |
+0,79% | 22,2 mld. | |
-17,84% | 21,23 mld. | |
-11,11% | 18,33 mld. | |
-42,83% | 16,35 mld. | |
-17,63% | 15,06 mld. | |
+4,55% | 13,98 mld. | |
+32,11% | 11,66 mld. |